Sovesudil clinical trials
Also written AMA0076.
How each study uses sovesudil is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses sovesudil is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular HypertensionStatus unknownPhase 3pH PharmaNCT04863365Written as PHP-201 ophthalmic solution
- Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension GlaucomaCompletedPhase 2pH PharmaNCT03106532Written as PHP-201 0.25% ophthalmic solution
- PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy SubjectsCompletedPhase 1pH PharmaNCT03586908Written as PHP-201 0.5% ophthalmic solution (topical eye drop)
- Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionCompletedPhase 2Amakem, NVNCT02136940Written as AMA0076
- A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy SubjectsCompletedPhase 1Amakem, NVNCT02003547Written as AMA0076
- Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle GlaucomaCompletedPhase 2Amakem, NVNCT01693315Written as AMA0076
Codes
What other systems call sovesudil · ClinicalTrials.gg INT001924
- UNII (FDA) C23O3R93BMSOVESUDILOne source FDA
- NCI Thesaurus C174648SovesudilOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | C23O3R93BM | SOVESUDIL | One source FDA |
| NCI Thesaurus | C174648 | Sovesudil | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.